Factor b proteases
AssigneeVertex Pharmaceuticals Incorporated
InventorsMikhail POPKOV, Vanessa SOROS, Natacha LE MOAN, Grant E. BLOUSE, Timothy MYLES
Life of this patent
Estimating the term…
Abstract
Provided herein are engineered proteases of the S1A family that are specific for, and capable of, cleaving Factor B. Also provided herein are methods of making and using such engineered proteases. The engineered proteases provided herein may be useful for treating a disease or condition associated with dysregulation of the complement system by reducing complement activation through cleavage and inactivation of Factor B.
Claims58
An engineered protease comprising a modified chymase protease domain, a modified membrane type serine protease 1 (MTSP-1) protease domain, a modified urokinase-type plasminogen activator (uPA) protease domain, or a modified Kallikrein-related peptidase 5 (KLK5) protease domain, wherein the engineered protease is capable of cleaving Factor B.
-4. (canceled)
-8. (canceled)
-11. (canceled)
(canceled)
(canceled)
(canceled)
(canceled)
-22. (canceled)
(canceled)
(canceled)
-29. (canceled)
-32. (canceled)
(canceled)
-37. (canceled)
(canceled)
(canceled)
-45. (canceled)
-48. (canceled)
(canceled)
(canceled)
-58. (canceled)
-61. (canceled)
(canceled)
(canceled)
(canceled)
-84. (canceled)
-87. (canceled)
Dependencies are inferred from the claim text.